My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cue Biopharma, Inc. - Common Stock (NQ:CUE)

0.7050 -0.0137 (-1.91%)
Streaming Delayed Price Updated: 11:45 AM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cue Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Cue Biopharma Inc (NASDAQ:CUE) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected
Cue Biopharma beats Q2 2025 revenue and EPS estimates, reports $2.95M revenue (-$0.09 EPS). Stock rises 2% amid FDA progress for CUE-401 autoimmune therapy. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
What's going on in today's after hours session
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Discover the top movers in Monday's pre-market session.
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
What's Going On With Cue Biopharma Shares Tuesday?
Cue reported 2024 fiscal-year earnings on Monday after the market closed. 
Via Benzinga
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Strategic Organizational Transition
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Proposed Public Offering
From Cue Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.